MX2022016127A - Proceso para la elaboracion de compuestos piridazina 1,4-disustituidos. - Google Patents

Proceso para la elaboracion de compuestos piridazina 1,4-disustituidos.

Info

Publication number
MX2022016127A
MX2022016127A MX2022016127A MX2022016127A MX2022016127A MX 2022016127 A MX2022016127 A MX 2022016127A MX 2022016127 A MX2022016127 A MX 2022016127A MX 2022016127 A MX2022016127 A MX 2022016127A MX 2022016127 A MX2022016127 A MX 2022016127A
Authority
MX
Mexico
Prior art keywords
manufacture
pyridazine compounds
disubstituted pyridazine
disubstituted
compounds
Prior art date
Application number
MX2022016127A
Other languages
English (en)
Inventor
Fabrice Gallou
Jianguang Zhou
Jiong Ye
Nicolas Amiot
Darija Dedic
Peng Fu
Xingxian Gu
Cornelius Harlacher
Siqian Liu
Shuping Yao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2022016127A publication Critical patent/MX2022016127A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/12—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La invención se refiere a un proceso novedoso, paso(s) de proceso novedoso e intermediario(s) novedoso(s) de utilidad para la preparación de compuestos piridazina 1,4-disustituidos, tal como 5-(1H-Pirazol-4-il)-2-(6-((2,2,6,6-tetrametilpiperidin-4-il)oxi)p iridazin-3-il)fenol.
MX2022016127A 2020-06-25 2021-06-24 Proceso para la elaboracion de compuestos piridazina 1,4-disustituidos. MX2022016127A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020098302 2020-06-25
CN2021083995 2021-03-30
PCT/IB2021/055593 WO2021260609A1 (en) 2020-06-25 2021-06-24 Process for the manufacture of 1,4-disubstituted pyridazine compounds

Publications (1)

Publication Number Publication Date
MX2022016127A true MX2022016127A (es) 2023-02-09

Family

ID=76730941

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016127A MX2022016127A (es) 2020-06-25 2021-06-24 Proceso para la elaboracion de compuestos piridazina 1,4-disustituidos.

Country Status (13)

Country Link
US (1) US20230348420A1 (es)
EP (1) EP4172148A1 (es)
JP (1) JP2023530761A (es)
KR (1) KR20230027177A (es)
CN (1) CN115916757A (es)
AU (1) AU2021298257A1 (es)
BR (1) BR112022025797A2 (es)
CA (1) CA3182324A1 (es)
CO (1) CO2022016096A2 (es)
IL (1) IL298261A (es)
MX (1) MX2022016127A (es)
TW (1) TW202216671A (es)
WO (1) WO2021260609A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE42214B1 (en) * 1974-06-18 1980-07-02 Smith Kline French Lab Hydrazinopyredazines
ES2533065T3 (es) * 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
ES2879995T3 (es) * 2015-12-10 2021-11-23 Ptc Therapeutics Inc Métodos para el tratamiento de la enfermedad de Huntington
KR20210005559A (ko) * 2018-03-27 2021-01-14 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물

Also Published As

Publication number Publication date
CN115916757A (zh) 2023-04-04
JP2023530761A (ja) 2023-07-19
WO2021260609A1 (en) 2021-12-30
IL298261A (en) 2023-01-01
EP4172148A1 (en) 2023-05-03
CA3182324A1 (en) 2021-12-30
BR112022025797A2 (pt) 2023-01-10
TW202216671A (zh) 2022-05-01
CO2022016096A2 (es) 2022-11-29
US20230348420A1 (en) 2023-11-02
AU2021298257A1 (en) 2022-11-03
KR20230027177A (ko) 2023-02-27

Similar Documents

Publication Publication Date Title
CR20210215A (es) Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
TW201129555A (en) Process for the manufacture of dabigatrane etexilate
MX2020002674A (es) Produccion de xilitol a partir de glucosa mediante una cepa recombinante.
WO2007035629A3 (en) Process for the preparation of pyrimidinedione derivatives
MX2019012815A (es) Proceso para la preparacion de compuestos de 2,3-dihidrotiazolo[3, 2-a]pirimidin-4-io opticamente activo.
PH12015501026A1 (en) Fungicide pyrazole carboxamides derivatives
PH12021550931A1 (en) New anthelmintic compounds
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
MX2019007452A (es) Proceso para preparar derivados de 7h-pirrolo[2,3-d]pirimidina y co-cristales de los mismos.
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
AU2020231934A8 (en) Compounds useful in HIV therapy
BR112021018578A2 (pt) Compostos de heterociclil(fenil)metanol úteis no tratamento de hiperglicemia
MX2022002418A (es) Composiciones y metodos de tratamiento de enfermedades vasculares.
MX2021000328A (es) Enzimas de variantes de galactosa oxidasa modificadas geneticamente.
MX2017015606A (es) Proceso para preparar 3-metilciclopentadecan-1,5-diona.
MX2019007137A (es) Fenilamidinas y su uso como fungicidas.
MX2022016127A (es) Proceso para la elaboracion de compuestos piridazina 1,4-disustituidos.
MX2018008966A (es) Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.
WO2008125353A3 (de) Bearbeitungsmaschine für eine abtragende und für eine aufbauende bearbeitung
MX2019011649A (es) Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazoli n-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol.
MX2012010084A (es) Compuestos utiles para tratar transtornos neurodegenerativos.
PH12019500808A1 (en) Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof
MX2021005343A (es) Proceso para la preparacion de isoxazolinas opticamente enriquecidas.
IL279168B (en) A process for the preparation of eribulin
MY187204A (en) Process for the production of titanium dioxide, and titanium dioxide obtained thereby